Summary
Enthusiasm for the use of prophylactic aspirin for primary prevention of cardiovascular disease has been greatly exaggerated.
This is a preview of subscription content, log in via an institution to check access.
References
Relman AS: Aspirin for the primary prevention of myocardial infarction.N Eng J Med 1988; 318:245–246.
The Steering Committee of the Physicians' Health Study Research Group: Preliminary Report: Findings from the aspirin component of the ongoing Physicians' Health Study.N Engl J Med 1988; 318:262–264.
Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndromes.Circulation 1988; 77:1213–1220.
Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors.Br Med J 1988; 296:313–316.
Orme M. Aspirin all around.Br Med J 1988;296:307–308.
Fuster V, Cohen M, Chesebro JH. Usefulness of aspirin for coronary artery disease.Am J Cardiol 1988; 61:637–640.
Rights and permissions
About this article
Cite this article
Chesebro, J.H., Opie, L.H. & Fuster, V. The recent trials for aspirin in the prevention of cardiovascular mortality. Cardiovasc Drug Ther 3, 353–354 (1989). https://doi.org/10.1007/BF01858107
Issue Date:
DOI: https://doi.org/10.1007/BF01858107